DKDRF yields 4.40% · JNJ yields 2.14%● Live data
📍 DKDRF pulled ahead of the other in Year 1
Combined, DKDRF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of DKDRF + JNJ for your $10,000?
NewMed Energy - Limited Partnership engages in the exploration, development, production, and sale of petroleum, natural gas, and condensate in Israel and Cyprus. The company holds interests in the Leviathan project, which covers an area of 500 km2 located to the west of the shores of Haifa; the Block 12 that covers an area of approximately 386 km2 located in Cyprus; and the Yam Tethys project, which covers an area of 500 km2 located to the west of the shores of Ashkelon. It also holds interests in the New Ofek license that covers an area of approximately 344 km2 located in Israel; the New Yahel license, covering an area of 397.5 km2 located in Israel; and the Tanin and Karish leases covering an area of approximately 500km2 located to the west of the shores of Nahariya. The company serves independent power producers and various industrial enterprises. NewMed Energy Management Ltd. serves as the general partner of the company. The company was formerly known as Delek Drilling - Limited Partnership and changed its name to NewMed Energy - Limited Partnership in February 2022. NewMed Energy - Limited Partnership was incorporated in 1993 and is based in Herzliya, Israel. NewMed Energy - Limited Partnership is a subsidiary of Delek Energy Systems Ltd.
Full DKDRF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.